Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.

Wei GuoSonghua CaiFan ZhangFei ShaoGuochao ZhangYang ZhouLiang ZhaoFengwei TanShugeng GaoJie He

Published in: Thoracic cancer (2019)

The SII is a promising prognostic predictor for patients with surgically resected NSCLC and retained prognostic significance in the lung adenocarcinoma subgroup. The prognostic value of the SII is superior to the NLR and PLR.

Keyphrases

lymph node
small cell lung cancer
oxidative stress
prognostic factors
advanced non small cell lung cancer
randomized controlled trial
clinical trial
phase iii
brain metastases
drug induced